ENCAPS wins top honours at WRIQ's Lithium Battery Innovation Challenge
BRISBANE, Australia, Oct. 22, 2025 /PRNewswire/ -- The Waste Recycling Industry Association Queensland (WRIQ) has announced ENCAPS as the overall winner of the 2025 Lithium Battery Innovation Challenge, recognising its outstanding contribution to...
GAC at the Canton Fair: Exploring a New Collaborative Model of Globalization for Chinese Enterprises -- Products, Ecosystems, and Culture
GAUNGZHOU, China, Oct. 20, 2025 /PRNewswire/ -- On October 15, as a leading force in China's automotive industry going global, GAC participated in the 138th Canton Fair under the theme "Where Craft Meets Technology." Blending Lingnan cultural...
The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). OS was significantly...
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of...
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of s mall m olecule GLP-1 receptor ( GLP-1R) a gonist ASC30 in 65 participants...
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a...
From Test Drive to Co-Creation -- The 2025 Chery International User Summit Builds a New Mobility Ecosystem
WUHU, China, Oct. 19, 2025 /PRNewswire/ -- From October 17 to 21, under the theme "Co-Create • Co-Define," the 2025 Chery International User Summit gathered 1,200 guests from over 100 countries and regions in Wuhu. The event offered an immersive...
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3...
From "Wheels" to a "Three-Dimensional Ecosystem": The 2025 Chery Global Innovation Conference Unveils a New Blueprint for Intelligent Mobility
WUHU, China, Oct. 18, 2025 /PRNewswire/ -- A clear and composed "Hello everyone, I'm Mornine" ignited the climax of the 2025 Chery Global Innovation Conference. This unique "presenter" was none other than AiMOGA robot Mornine. In a ten-minute fully...
KLN Wins GBA Excellence in Logistics Solutions Award at the Hong Kong Economic Journal GBA Brand Awards of Excellence 2025
HONG KONG, Oct. 17, 2025 /PRNewswire/ -- KLN Logistics Group Limited ("KLN"; Stock Code 0636.HK) has won the title of GBA Excellence in Logistics Solutions Award at the Hong Kong Economic Journal GBA Brand Awards of Excellence 2025 (the 'Awards'),...